Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells

Leukemia Research

Volumn 35, Issue 4, 2011, Pages 551-559

  Holstein, Sarah A ^a   Hohl, Raymond J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Apoptosis; GGTase II; Multiple myeloma; Secretion; Unfolded protein response

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; DIMETHYLALLYLTRANSFERASE; FARNESYL TRANS TRANSFERASE; GGT 2133; GGTI 2133; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAB PROTEIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CANCER INHIBITION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN SECRETION;

APOPTOSIS; BIOSYNTHETIC PATHWAYS; CELL LINE, TUMOR; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMIDAZOLES; IMMUNOBLOTTING; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; LOVASTATIN; MULTIPLE MYELOMA; PRENYLATION; RAB1 GTP-BINDING PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TERPENES; TUNICAMYCIN; UNFOLDED PROTEIN RESPONSE;

EID: 79952360375     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.08.008     Document Type: Article

References (38)

1. Brewer J.W., Hendershot L.M. Building an antibody factory: a job for the unfolded protein response. Nat Immunol 2005, 6:23-29.
2. Malhotra J.D., Kaufman R.J. The endoplasmic reticulum and the unfolded protein response. Semin Cell Dev Biol 2007, 18:716-731.
3. Gunn K.E., Gifford N.M., Mori K., Brewer J.W. A role for the unfolded protein response in optimizing antibody secretion. Mol Immunol 2004, 41:919-927.
4. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
5. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10:1478-1487.
6. Koizumi M., Nakaseko C., Ohwada C., Takeuchi M., Ozawa S., Shimizu N., et al. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Eur J Haematol 2007, 79:382-391.
7. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999, 264:108-111.
8. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000, 373:231-241.
9. van de Donk N.W., Kamphuis M.M., Lokhorst H.M., Bloem A.C. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002, 16:1362-1371.
10. Holstein S.A., Tong H., Hohl R.J. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leuk Res 2010, 34:344-351.
11. Ochiai N., Uchida R., Fuchida S., Okano A., Okamoto M., Ashihara E., et al. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 2003, 102:3349-3353.
12. Roelofs A.J., Hulley P.A., Meijer A., Ebetino F.H., Russell R.G., Shipman C.M. Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer 2006, 119:1254-1261.
13. van de Donk N.W., Kamphuis M.M., van Kessel B., Lokhorst H.M., Bloem A.C. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003, 102:3354-3362.
14. Schultz J., Doerks T., Ponting C.P., Copley R.R., Bork P. More than 1,000 putative new human signalling proteins revealed by EST data mining. Nat Genet 2000, 25:201-204.
15. Fukuda M. Regulation of secretory vesicle traffic by Rab small GTPases. Cell Mol Life Sci 2008, 65:2801-2813.
16. Gomes A.Q., Ali B.R., Ramalho J.S., Godfrey R.F., Barral D.C., Hume A.N., et al. Membrane targeting of Rab GTPases is influenced by the prenylation motif. Mol Biol Cell 2003, 14:1882-1899.
17. Vishnuvardhan D., Beinfeld M.C. Lovastatin is a potent inhibitor of cholecystokinin secretion in endocrine tumor cells in culture. Peptides 2000, 21:553-557.
18. Ostrowski S.M., Wilkinson B.L., Golde T.E., Landreth G. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J Biol Chem 2007, 282:26832-26844.
19. Moreau A.S., Jia X., Patterson C.J., Roccaro A.M., Xu L., Sacco A., et al. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol 2008, 142:775-785.
20. Shull L.W., Wiemer A.J., Hohl R.J., Wiemer D.F. Synthesis and biological activity of isoprenoid bisphosphonates. Bioorg Med Chem 2006, 14:4130-4136.
21. Coxon F.P., Helfrich M.H., Larijani B., Muzylak M., Dunford J.E., Marshall D., et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 2001, 276:48213-48222.
22. Ohno S., Yoshimoto M., Honda S., Miyachi S., Ishida T., Itoh F., et al. The antisense approach in amyloid light chain amyloidosis: identification of monoclonal Ig and inhibition of its production by antisense oligonucleotides in in vitro and in vivo models. J Immunol 2002, 169:4039-4045.
23. Bergstrom J.D., Kurtz M.M., Rew D.J., Amend A.M., Karkas J.D., Bostedor R.G., et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci USA 1993, 90:80-84.
24. Tong H., Holstein S.A., Hohl R.J. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal Biochem 2005, 336:51-59.
25. Misumi Y., Miki K., Takatsuki A., Tamura G., Ikehara Y. Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J Biol Chem 1986, 261:11398-11403.
26. Takizawa T., Tatematsu C., Watanabe K., Kato K., Nakanishi Y. Cleavage of calnexin caused by apoptotic stimuli: implication for the regulation of apoptosis. J Biochem 2004, 136:399-405.
27. Ron D., Habener J.F. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992, 6:439-453.
28. Ma Y., Brewer J.W., Diehl J.A., Hendershot L.M. Two distinct stress signaling pathways converge upon the CHOP promoter during the mammalian unfolded protein response. J Mol Biol 2002, 318:1351-1365.
29. Holstein S.A., Wohlford-Lenane C.L., Hohl R.J. Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry 2002, 41:13698-13704.
30. Rao S., Porter D.C., Chen X., Herliczek T., Lowe M., Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999, 96:7797-7802.
31. Coxon F.P., Ebetino F.H., Mules E.H., Seabra M.C., McKenna C.E., Rogers M.J. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 2005, 37:349-358.
32. Holstein S.A., Wohlford-Lenane C.L., Hohl R.J. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB. J Biol Chem 2002, 277:10678-10682.
33. Ramalho J.S., Anders R., Jaissle G.B., Seeliger M.W., Huxley C., Seabra M.C. Rapid degradation of dominant-negative Rab27 proteins in vivo precludes their use in transgenic mouse models. BMC Cell Biol 2002, 3:26.
34. Kimmel D.B. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007, 86:1022-1033.
35. Shipman C.M., Croucher P.I., Russell R.G., Helfrich M.H., Rogers M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58:5294-5297.
36. Lawson M.A., Coulton L., Ebetino F.H., Vanderkerken K., Croucher P.I. Geranylgeranyl transferase type II inhibition prevents myeloma bone disease. Biochem Biophys Res Commun 2008, 377:453-457.
37. Schmidmaier R., Baumann P., Bumeder I., Meinhardt G., Straka C., Emmerich B. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 2007, 79:240-243.
38. Fuchs D., Berges C., Opelz G., Daniel V., Naujokat C. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem Biophys Res Commun 2008, 374:309-314.